Trelagliptin is a selective DPP-4 inhibitor and certified reference standard developed for the treatment of type 2 diabetes mellitus. As the active pharmaceutical ingredient marketed as Zafatek® in Japan, Trelagliptin provides effective glycemic control through a once-weekly dosing regimen. In pharmaceutical quality control contexts, Trelagliptin serves as the primary reference standard for impurity profiling, analytical method development, and regulatory submissions. Trelagliptin is recognized through multiple regulatory designations including INN, USAN, and JAN, making it indispensable for ANDA filings and quality control testing. The drug substance Trelagliptin exhibits excellent stability when stored under recommended conditions. Furthermore, Trelagliptin is a potent inhibitor of DPP-4 with an IC₅₀ of 3.9 nM, demonstrating the exceptional potency of this well-characterized molecular scaffold.
|
Parameter |
Specification |
|
Product Name |
Trelagliptin |
|
CAS Number |
865759-25-7 |
|
Molecular Formula |
C₁₈H₂₀FN₅O₂ |
|
Molecular Weight |
357.38 g/mol |
|
Appearance |
White solid |
|
Boiling Point |
519.0 ± 60.0 °C |
|
Density |
1.38 ± 0.1 g/cm3 |
|
Storage Condition |
–20°C, protect from light |
Trelagliptin, with the chemical name 2-[{6-[(3R)-3-amino-piperidine-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-pyrimidin-1(2H)-yl}-methyl]-4-fluorobenzonitrile, is an effective dipeptidyl peptidase IV (DPP-4) inhibitor developed by Takeda Pharmaceutical Company Limited in Japan. By selectively and persistently inhibiting DPP-4, trelagliptin helps control blood glucose levels. Trelagliptin demonstrates excellent safety and tolerability; a once-weekly dosing regimen can effectively manage blood glucose levels and improve patient adherence to treatment. It is indicated for the treatment of type 2 diabetes mellitus.
Trelagliptin (SYR-472) is a highly selective long-acting DPP-4 inhibitor.
Once-Weekly DPP-4 Inhibitor
Trelagliptin is a highly potent DPP-4 inhibitor with an IC₅₀ of 3.9 nM, enabling once-weekly oral administration. This extended dosing interval offers significant advantages over once-daily DPP-4 inhibitors in improving patient adherence to anti-diabetic therapy.
Highly Potent and Selective
The molecular structure of Trelagliptin confers exceptional potency and selectivity for DPP-4, ensuring effective glycemic control with minimal off-target effects.
Clinically Validated Efficacy
Trelagliptin is approved in Japan as Zafatek® for the treatment of type 2 diabetes, validating its safety and efficacy in clinical practice.
Dual-Use: API and Reference Standard
Cosperpharm supplies Trelagliptin at high-purity grade for use in both research applications and as an analytical reference standard for method development and quality control programs.
Partner with Cosperpharm for Trelagliptin that delivers the purity, documentation, and supply reliability your research program requires.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
